USANA Health Sciences, Inc. — Form 10-Q Summary
Period discrepancy: The supplied filing is for the quarter ended October 1, 2022, not 2021 Q3 as stated in the request. Comparisons below are with the quarter ended October 2, 2021.
Business context and reporting period
USANA develops and sells nutritional, food, personal-care, and skincare products internationally through independent Associates and Preferred Customers. It reported approximately 474,000 active Customers at October 1, 2022, down 17.7% year over year. Asia Pacific generated 78.3% of quarterly sales; China alone generated $97.4 million.
Financial results
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Net sales | $233.3 million | $274.4 million | $770.6 million | $919.2 million |
| Gross profit | $186.7 million | $223.6 million | $623.2 million | $753.8 million |
| Gross margin | 80.0% | 81.5% | 80.9% | 82.0% |
| Operating earnings | $22.6 million | $40.8 million | $85.1 million | $138.7 million |
| Net earnings | $14.9 million | $27.3 million | $56.6 million | $96.2 million |
| Diluted EPS | $0.78 | $1.36 | $2.93 | $4.68 |
For the first nine months, operating cash flow was $63.4 million, compared with $96.3 million a year earlier. Investing cash flow was negative $9.1 million and financing cash flow was negative $29.9 million. Cash and cash equivalents were $246.9 million at October 1, 2022, versus $239.8 million at January 1, 2022. Current assets were $341.2 million and current liabilities $125.8 million. No borrowings were outstanding under the $75 million revolving credit facility at quarter-end.
Material changes versus the prior comparable period
- Q3 sales fell 15.0%; management estimated unfavorable currency movements reduced sales by $15.0 million. Excluding currency effects, sales declined 9.5%.
- Nine-month sales fell 16.2%; excluding currency effects, they declined 13.0%.
- Management attributed lower sales primarily to fewer active Customers, COVID-related lockdown disruptions, weaker-than-expected promotions, and inflationary and economic pressures, particularly in Asia Pacific.
- Q3 gross margin contracted 150 basis points. Management cited foreign exchange, inventory valuation adjustments, higher material costs, and reduced leverage on lower sales.
- Q3 net earnings decreased 45.4%. Selling, general and administrative expense was roughly flat in dollars but increased as a share of sales because of lower revenue.
- Foreign-currency translation reduced nine-month comprehensive income: other comprehensive loss, net of tax, was $20.5 million.
Outlook, risks, contingencies, and unusual items
- No specific revenue or earnings guidance is provided. Management said cash balances, expected operating cash flow, and available credit should cover ordinary operating and capital needs for the foreseeable future.
- Management said the effects of COVID-19 remained uncertain and could continue to disrupt sales, operations, supply chains, and logistics. Inflation and currency volatility were also cited as pressures.
- The company must maintain rolling four-quarter credit-agreement EBITDA of at least $100 million and funded debt to EBITDA of no more than 2.0 to 1.0. The facility matures in August 2025.
- Ordinary-course legal matters were disclosed; management did not believe they would have a material adverse effect, though some contingencies could not currently be estimated.
- Second-quarter asset acquisitions involved $6.5 million cash consideration and $0.9 million contingent consideration; related revenue and earnings were immaterial.
- Management reported no goodwill or indefinite-lived intangible impairment in its annual third-quarter assessments. It also reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the reporting-period mismatch: the supplied 10-Q is for Q3 2022, despite the request identifying 2021 Q3.
- Track active-Customer trends and sales performance by region, especially China and Southeast Asia Pacific.
- Assess whether lower sales, margin pressure, and operating cash flow persist, and monitor the impact of foreign exchange and inflation.
- Review compliance with credit-facility covenants and the ability to remit funds from China, where transfers may be delayed by regulatory requirements.
- Consider the uncertainty around COVID-related disruptions, supply-chain costs, and the disclosed legal contingencies.